These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17396201)

  • 1. Cilostazol, a phosphodiesterase III inhibitor: future perspectives in atherosclerosis.
    da Rosa MP; Baroni GV; Portal VL
    Arq Bras Cardiol; 2006 Nov; 87(5):e222-6. PubMed ID: 17396201
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of cilostazol, a selective type-III phosphodiesterase inhibitor, on water-immersion stress-induced gastric mucosal injury in rats.
    Ohba R; Otaka M; Odashima M; Jin M; Komatsu K; Konishi N; Wada I; Horikawa Y; Matsuhashi T; Oyake J; Hatakeyama N; Watanabe S
    J Gastroenterol; 2006 Jan; 41(1):34-40. PubMed ID: 16501855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
    Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
    Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma.
    Fujimura M; Kamio Y; Myou S; Hashimoto T; Matsuda T
    Int Arch Allergy Immunol; 1997 Dec; 114(4):379-84. PubMed ID: 9414143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory action of cilostazol, a phosphodiesterase III inhibitor, on catecholamine secretion from cultured bovine adrenal chromaffin cells.
    Azuma M; Houchi H; Mizuta M; Kinoshita M; Teraoka K; Minakuchi K
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S29-32. PubMed ID: 12688393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phospshodiesterase in rats.
    Odashima M; Otaka M; Ohba R; Jin M; Wada I; Horikawa Y; Matsuhashi T; Hatakeyama N; Oyake J; Watanabe S
    Dig Dis Sci; 2007 May; 52(5):1355-9. PubMed ID: 17372821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
    Nakamura K; Ikomi F; Ohhashi T
    J Vasc Res; 2006; 43(1):86-94. PubMed ID: 16286783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation.
    Kim MJ; Lee JH; Park SY; Hong KW; Kim CD; Kim KY; Lee WS
    Pharmacol Res; 2006 Oct; 54(4):261-7. PubMed ID: 16822680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol in the management of vascular disease.
    Dalainas I
    Int Angiol; 2007 Mar; 26(1):1-7. PubMed ID: 17353881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells.
    Wu SN; Liu SI; Huang MH
    Endocrinology; 2004 Mar; 145(3):1175-84. PubMed ID: 14645120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 12. Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
    Ikewaki K; Mochizuki K; Iwasaki M; Nishide R; Mochizuki S; Tada N
    Metabolism; 2002 Oct; 51(10):1348-54. PubMed ID: 12370857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.
    Ye YL; Shi WZ; Zhang WP; Wang ML; Zhou Y; Fang SH; Liu LY; Zhang Q; Yu YP; Wei EQ
    Eur J Pharmacol; 2007 Feb; 557(1):23-31. PubMed ID: 17161838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow.
    Birk S; Kruuse C; Petersen KA; Jonassen O; Tfelt-Hansen P; Olesen J
    J Cereb Blood Flow Metab; 2004 Dec; 24(12):1352-8. PubMed ID: 15625409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic and clinical characteristics of PDE 3 inhibitors as cardiotonic agents.
    Endoh M
    Cardiovasc Drugs Ther; 2007 Jun; 21(3):135-9. PubMed ID: 17508272
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo.
    Minami N; Suzuki Y; Yamamoto M; Kihira H; Imai E; Wada H; Kimura Y; Ikeda Y; Shiku H; Nishikawa M
    Life Sci; 1997; 61(25):PL 383-9. PubMed ID: 9416770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination therapy with PDE III inhibitor for heart failure].
    Watanabe H; Kajimoto K; Kawana M
    Nihon Rinsho; 2007 May; 65 Suppl 5():134-9. PubMed ID: 17571377
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture.
    Takahashi S; Oida K; Fujiwara R; Maeda H; Hayashi S; Takai H; Tamai T; Nakai T; Miyabo S
    J Cardiovasc Pharmacol; 1992 Dec; 20(6):900-6. PubMed ID: 1282592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The mode of action and clinical applications of phosphodiesterase inhibitors as anti-platelet drugs].
    Murohara Y; Takatsu Y; Yui Y; Kawai C
    Nihon Rinsho; 1989 Apr; 47(4):935-9. PubMed ID: 2545947
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effects of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on pulmonary vascular tone].
    Shigemori K; Ishizaki T; Takahashi H; Sasaki F; Ameshima S; Ohnishi T; Sakai T; Nakai T; Miyabo S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Aug; 31(8):936-41. PubMed ID: 8230891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.